Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS9531 in Obese Subjects Without Diabetes
NCT05881837Phase 2Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Jun 2023
- Primary completion
- Oct 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HRS9531 in obesity (8 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoint: Percentage change in body weight at 32 weeks. Started Jun 2023; status: completed.
02
Drugs
HRS9531
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05881837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05881837.